Credit: PROFESSOR JOHN ZAJICEK/Science Source
And, importantly, view the impact of MS through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.
The road to a cure for MS lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The Multiple Sclerosis Journey. We invite you to join them.
Walk with us.
During the past few decades, research has made clear that multiple sclerosis causes not only physical disability but also cognitive problems.
When it comes to treating patients with multiple sclerosis (MS), a new study shows that physicians and nurse practitioners (NPs) score similarly in regard to patient satisfaction.
The cost of treatment for multiple sclerosis (MS) has been the subject of GoFundMe campaigns, an investigation by members of Congress, and recent studies in Neurology and JAMA Neurology.
Infusible disease-modifying therapies for multiple sclerosis (MS) are disproportionately more effective at quelling disease activity than oral drugs in younger patients, an advantage that fades by about age 45 years, Enrique Alvarez, MD, PhD, reported at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Monitoring immunoglobulin levels regularly has become an imperative in patients with multiple sclerosis (MS) on anti-CD20 agents in light of consistent findings from long-term, open-label studies of rituximab and ocrelizumab presented at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.